Vaxcyte (NASDAQ: PCVX)
$40.13
(5.5%)
$2.10
Price as of October 2, 2025, 4:00 p.m. ET
Vaxcyte Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Vaxcyte Company Info
Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, and Jeff Fairman on November 27, 2013 and is headquartered in San Carlos, CA.
News & Analysis
Featured Article
Vaxcyte (PCVX) Q2 Loss Widens 11%
Motley Fool Markets Team | Aug 6, 2025
Featured Article
Why Shares of Vaxcyte Rose 110.7% This Week
The company released early data for a promising pneumonia vaccine.
James Halley | Oct 29, 2022
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.